FDA approves Apellis’ therapy to treat two serious, rare kidney diseases
HQ Team July 30, 2025: The US Food and Drug Administration has approved Apellis Pharmaceuticals, Inc.’s medicine for treating two rare and serious.
Drugs
Health
Pharma
Drugs
Health
Pharma
Kezar Life Sciences halts mid-stage lupus nephritis trial after four people die
Kezar Life Sciences Inc., a US-based biotechnology company, has stopped a trial in patients with a type of kidney disease after four people.